Skip to content

Effectiveness of Rapamune and Cograft drugs in the treatment of patients with kidney transplantation

Comparison the effectiveness of Rapamune and Cograft drugs in the treatment of kidney transplantation rejection

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016052914333N52
Enrollment
60
Registered
2016-06-27
Start date
2016-06-19
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Comparative Interventional Treatment for reduceing the renal transplant rejection. kidney transplant rejection

Interventions

Intervention 1: First intervention group in addition to routine drug, will receive 2 mg Rapamune every 24 hours for 6 months. Intervention 2: Second intervention group, in addition to routine drug wil
Treatment - Drugs
First intervention group in addition to routine drug, will receive 2 mg Rapamune every 24 hours for 6 months.
Second intervention group, in addition to routine drug will receive 1 mg Cograft every 12 hours for 6 months

Sponsors

Vice chancellor for research, Kermanshah University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with chronic renal failure who is the first referred for kidney transplant; Age 18-55 years; Lack of comorbidities such as active hepatitis C and B , HIV, Cancer, heart disease Exclusion criteria: vascular complications arising from graft surgery; Substitution treatment regimen for any reason in the middle to other immune suppressive therapy regimes

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Renal transplant rejection. Timepoint: During hospitalized for6month and 6month after renal transplant( weekly in the first month and once every two weeks in second and third month, and in the fourth and fifth months will be monthly). Method of measurement: Based on clinical findings, ultrasound, DTPA scan and renal biopsy.;Side effects. Timepoint: During hospitalized for6month and 6month after renal transplant( weekly in the first month and once every two weeks in second and third month, and in the fourth and fifth months will be monthly). Method of measurement: Based on clinical symptoms, physician observation and patient interview.

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026